World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: Netherlands Trial Register
Last refreshed on: 28 April 2013
Main ID:  NTR961
Date of registration: 16/04/2007
Primary sponsor: University Hospital Ghent, dept of Gyneacology
Public title: A multi-centre, randomized, double-blind trial studying the effect of misoprostol on the outcome of intra-uterine insemination.
Scientific title: A multi-centre, randomized, double-blind trial studying the effect of misoprostol on the outcome of intra-uterine insemination. - A multi-centre, randomized, double-blind trial studying the effect of misoprostol on the outcome of intra-uterine insemination.
Date of first enrolment: 1/10/2003
Target sample size: 217
Recruitment status: complete
URL:  http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=961
Study type:  intervention
Study design:  Randomised: Yes; Masking: Double; Control: Placebo; Group: Crossover; Type: 2 or more arms, randomized  
Countries of recruitment
The Netherlands
Contacts
Name: M.  Dhont
Address:  Universitair Ziekenhuis Gent, Vrouwenziekten, De Pintelaan 185 9000 Gent Belgium
Telephone: +32 92403796
Email: Marc.Dhont@Ugent.be
Affiliation: 
Name: M.  Dhont
Address:  Universitair Ziekenhuis Gent, Vrouwenziekten, De Pintelaan 185 9000 Gent Belgium
Telephone: +32 92403796
Email: Marc.Dhont@Ugent.be
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. All women presenting for intra-uterine insemination;

2. Between the age of 20 and 36 years;

3. Bilateral tubal patency was proven;

4. Total motile fraction of the semen sample was more than 1 million after preparation;

5. Informed consent.

Exclusion criteria: 1. History of previously failed intra-uterine insemination;

2. Severe comorbidity (endometriosis, fibroma);

3. Previous allergic reactions to misoprostol.


Age minimum:
Age maximum:
Gender:
Health Condition(s) or Problem(s) studied
Pregnancy, Intra-uterine insemination (IUI), Misoprostol , Prostaglandin, Vaginal suppository

Intervention(s)
Before removing the speculum after IUI, a white study suppository is placed in het posterior vaginal fornix. Each suppository contains either placebo or 400 µg of misoprostol.
Primary Outcome(s)
Primary outcome is clinical pregnancy defined as the presence of a fetal sac with positive cardial activity.
Secondary Outcome(s)
Secondary endpoints are adverse reactions: uterine cramps and vaginal bleeding.
Secondary ID(s)
ISRCTN76424181
Source(s) of Monetary Support
Vlaamse vereniging voor obstetrie en gynaecologie
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history